Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating safety and immunogenicity of Nimenrix given at 3 and 12 months in healthy infants has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Nimenrix (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid)

Snippet

Sponsor: Pfizer | Conditions: Meningococcal Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2024-03-18